USA Anticoagulation Therapy Market Size and Growth Rate:
The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from an estimated USD 18.49 Billion in 2017, at a CAGR of 8.5%. Market growth is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs).
In this report, the US anticoagulation therapy market is segmented on the basis of products and clinics. On the basis of products, the market is segmented into anticoagulation drugs and PT/INR testing devices.
Based on drug type, the anticoagulation therapy market for drugs is segmented into NOACs, warfarin (VKA), and other drugs. In 2016, the NOACs segment dominated the US anticoagulation therapy market for drugs. Due to the better safety and efficacy of NOACs as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs. In addition, key market players such as Portola Pharmaceuticals (received FDA approval for its NOAC Betrixaban in July 2017) are focusing on the development of NOACs in order to capitalize on the growth opportunities presented by this shift in market dynamics. Consequently, many other companies are also expected to focus on developing more safe and efficient NOACs in the coming years; this will ensure the continued growth of this segment.
The anticoagulation therapy market for PT/INR testing devices is segmented into in-office testing devices and home testing devices. The in-office devices segment dominated the US anticoagulation therapy market for PT/INR testing devices. The large share of this segment is mainly attributed to the large number of patients opting for in-office testing services. However, the home testing devices segment is expected to grow at the highest CAGR due to its advantages such as convenience, time & cost savings, and quick result generation. Additionally, the cost of test devices and the tests themselves are often reimbursable.
The anticoagulation therapy market for clinics is segmented on the basis of type of services and clinics. The types of clinics include hospital associated clinics, independent clinics, and pharmacy-based clinics while the types of services include testing services and consulting services. The pharmacy-based clinics segment is expected to register the highest CAGR during the forecast period. In the US, the number of pharmacy-based anticoagulation clinics has increased significantly in the last few years. This is due to the fact that better results are achieved when therapy is managed by expert pharmacists rather than care provided by family physicians. Moreover, the cost of therapy provided by pharmacy-based anticoagulation clinics is comparatively lesser than independent and hospital associated anticoagulation clinics which is expected to drive the market for pharmacy-based anticoagulation clinics.
C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer (US), Daiichi Sankyo (Japan), and Portola Pharmaceuticals (US) are the major market players in the global market for drugs while Roche (Switzerland), Abbott (US), Siemens (Germany), Alere (US), and CoaguSense (US) are the major market players in the US anticoagulation therapy market for PT/INR home testing devices.
Table of Contents
1 Introduction (Page No. - 10)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Stakeholders
2 Research Methodology (Page No. - 13)
2.1 Research Approach
2.1.1 Secondary Data
2.1.2 Primary Data
2.1.2.1 Breakdown of Primary Interviews
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.2.1 Market Sizing Methodology for Anticoagulation Drugs and PT/INR Testing Devices
2.2.2 Market Sizing Methodology for Anticoagulation Therapy for Clinics
2.2.3 Market Breakdown and Data Triangulation
2.2.4 Market Share Estimation
2.2.5 Assumptions for the Study
3 Market Overview (Page No. - 23)
3.1 Market Dynamics: Anticoagulation Drugs
3.1.1 Drivers
3.1.1.1 Rising Incidence of Venous Thromboembolism, Atrial Fibrillation, and Stroke
3.1.1.2 Increasing Demand for Noacs as Alternatives to Warfarin
3.1.1.3 Growing Number of Patients Requiring Lifelong Anticoagulation Therapy
3.1.2 Market Restraints
3.1.2.1 High Price of Noacs
3.1.2.2 High Development Expenditure, Stringent Regulations
3.1.3 Market Opportunities
3.1.3.1 Increase in Outpatient Management of Anticoagulation Therapy
3.1.3.2 Development of Noac Reversal Agents
3.2 Market Dynamics: Anticoagulation Clinics
3.2.1 Key Market Drivers
3.2.1.1 Increasing Prevalence of Cvd and Blood Disorders
3.2.1.2 High Level of Medication Adherence
3.2.1.3 Growth in the Geriatric Population
3.2.2 Market Restraints
3.2.2.1 Rising Adoption of Noacs
3.2.2.2 Demand for Alternative Treatments
3.2.2.3 Home PT/INR Testing
3.2.3 Market Opportunities
3.2.3.1 Development of Alternative Approaches
4 Market Insights (Page No. - 33)
4.1 Introduction
4.2 Number of Anticoagulation Clinics
4.3 Business Models of Anticoagulation Clinics
4.3.1 Revenue Structure
4.3.2 Infrastructure Requirements for Sustaining in the Market
4.3.2.1 Role of Teleconsultation and Telemonitoring
4.3.2.2 Role of Electronic Health Record in Anticoagulation Clinics
4.4 Reimbursement Scenario (CMS & Private Payers)
4.4.1 Reimbursement Rate (2016–2017)
4.4.1.1 Reimbursement for PT/INR Testing
4.4.1.2 Reimbursement for Evaluation and Management Service Associated With Anticoagulation Therapy
4.4.2 Reimbursement Trends for Anticoagulation Therapy
4.5 Impact of New Oral Anticoagulants (Noacs) on Anticoagulation Clinics
5 US Anticoagulation Therapy (Products) Market (Page No. - 51)
5.1 US Anticoagulation Therapy (Products) Market for Drugs
5.1.1 Introduction
5.1.2 Novel Oral Anticoagulants
5.1.3 Warfarin (Vitamin K Antagonist)
5.1.4 Other Drugs
5.2 US Anticoagulation Therapy (Products) Market for PT/INR Testing Devices
5.2.1 Introduction
5.2.2 In-Office Testing Devices
5.2.3 Home Testing Devices
6 US Anticoagulation Therapy Market for Clinics (Page No. - 59)
6.1 Introduction
6.2 US Anticoagulation Therapy Market for Clinics, By Type of Service
6.2.1 Introduction
6.2.2 Testing Services
6.2.3 Consulting Services
6.3 US Anticoagulant Therapy Market for Clinics, By Type of Clinic
6.3.1 Introduction
6.3.2 Hospital Associated Clinics
6.3.3 Independent Clinics
6.3.4 Pharmacy-Based Clinics
7 Company Profiles (Page No. - 67)
(Business Overview, Products Offered, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments.)*
7.1 Introduction
7.2 Home Testing Devices Manufacturers
7.2.2 Abbott Laboratories
7.2.3 Siemens AG
7.2.4 Coagusense, Inc.
7.2.5 Alere Inc.
7.3 Drug Manufacturers
7.3.1 C. H. Boehringer Sohn AG & Co. Kg
7.3.2 Bristol-Myers Squibb Company
7.3.3 Johnson & Johnson
7.3.4 Pfizer, Inc.
7.3.5 Daiichi Sankyo Company, Limited
7.3.6 Portola Pharmaceuticals, Inc.
*Details on Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key Relationships Might Not Be Captured in Case of Unlisted Companies.
List of Tables (29 Tables)
Table 1 Impact Analysis: Market Drivers
Table 2 Cost Difference: Noac vs Warfarin, Per Patient Per Month, in the US (2015)
Table 3 Impact Analysis: Market Restraints
Table 4 Pipeline Assessment: Anticoagulant Reversal Agents
Table 5 Impact Analysis: Market Opportunities
Table 6 Impact Analysis: Market Drivers
Table 7 Impact Analysis: Market Restraints
Table 8 Impact Analysis: Market Opportunities
Table 9 Component Cost for Different Treatment Settings of Anticoagulation Clinics
Table 10 Laboratory PT/INR Testing Reimbursement Codes & Rates
Table 11 Physician-Directed Home PT/INR Testing Hcpcs Reimbursement Codes & Rates (National)
Table 12 Physician-Directed Home PT/INR Testing Hcpcs Reimbursement Rates (State-Wise)
Table 13 Home PT/INR Testing Service Reimbursement Ambulatory Payment Classifications (Apcs) Codes & Rates Under Hospital Outpatient Prospective Payment System
Table 14 State Regulatory Bodies for PT/INR Test Reimbursement
Table 15 Reimbursement Rate for E&M Services During Anticoagulation Therapy (2015)
Table 16 Physician-Directed Home PT/INR Testing Hcpcs Reimbursement Codes & Rates, 2009 vs 2016 (National Rate)
Table 17 Laboratory PT/INR Testing Reimbursement Codes & Rates, 2009 vs 2016 (National Rate)
Table 18 Preliminary Payment Rates in 2018, 2019, and 2020 (With 10% Reduction Cap Wherever Applicable)
Table 19 Coagulation Assay Responsiveness to Noacs
Table 20 US Anticoagulation Therapy (Products) Market for Drugs, By Type, 2015–2022 (USD Million)
Table 21 List of Novel Oral Anticoagulants Available in the US Market
Table 22 Average Cost of Oral Anticoagulants Per Patient Per Month in the US (2015)
Table 23 US Anticoagulation Therapy (Products) Market for PT/INR Testing Devices, By Type, 2015–2022 (USD Million)
Table 24 US In-Office PT/INR Testing Devices Market, 2015–2022 (USD Million)
Table 25 Leading Home Testing Devices Available in the US Market
Table 26 Statistics of Thromboembolic Conditions in the Us
Table 27 US Anticoagulation Therapy Market for Clinics, By Type of Service, 2015–2022 (USD Million)
Table 28 Major Anticoagulation Clinics in the Us
Table 29 US Anticoagulant Therapy Market for Clinics, By Type of Clinic, 2015–2022 (USD Million)
List of Figures (25 Figures)
Figure 1 US Anticoagulation Therapy Market Segmentation
Figure 2 Secondary Research Approach
Figure 3 Primary Research Approach
Figure 4 Market Sizing Approach
Figure 5 Data Triangulation Methodology
Figure 6 US Anticoagulation Drugs Market: Drivers, Restraints, and Opportunities
Figure 7 US Anticoagulation Therapy Market for Clinics: Drivers, Restraints & Opportunities
Figure 8 Number of Patient Visits to Anticoagulation Clinics, By Line of Therapy (2016 vs 2022)
Figure 9 Average Number/ Percentage Share of Noac Therapy Patients Visiting Anticoagulant Clinics, 2015 vs 2020
Figure 10 Evolution of Anticoagulants
Figure 11 Percentage of Anticoagulants Prescribed for Different Indications
Figure 12 Noacs, the Largest Segment in the US Anticoagulation Therapy (Products) Market for Drugs
Figure 13 In-Office Testing Devices, the Largest Segment in the US Anticoagulation Therapy (Products) Market for PT/INR Testing Devices
Figure 14 Testing Services to Dominate the global Market for Clinics in 2017
Figure 15 Hospital-Associated Clinics Segment Will Continue to Dominate the US Anticoagulation Therapy Market for Clinics in 2022
Figure 16 F. Hoffmann-La Roche AG: Company Snapshot (2016)
Figure 17 Abbott Laboratories: Company Snapshot (2016)
Figure 18 Siemens AG: Company Snapshot (2016)
Figure 19 Alere Inc.: Company Snapshot (2016)
Figure 20 C. H. Boehringer Sohn AG & Co. Kg: Company Snapshot (2016)
Figure 21 Bristol-Myers Squibb Company: Company Snapshot (2016)
Figure 22 Johnson & Johnson: Company Snapshot (2016)
Figure 23 Pfizer, Inc.: Company Snapshot (2016)
Figure 24 Daiichi Sankyo Company, Limited: Company Snapshot (2015)
Figure 25 Portola Pharmaceuticals, Inc.: Company Snapshot (2016)
+1 888 709 8757
Chat With Us